Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

U.S. regulators extended the review period for Exelixis' request to approve a new cancer drug, delaying a decision. The company's most important medicine is performing well and has several years of growth runway before generic competition, partially offsetting the regulatory delay.